---
title: "Gilead Sciences (GILD) Gets a Hold from RBC Capital"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293825749.md"
description: "RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD) with a $120 price target, noting shares closed at $130.86. While Goldman Sachs also issued a Hold, BMO Capital assigned a Buy rating to the stock on July 23."
datetime: "2026-07-25T14:45:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293825749.md)
  - [en](https://longbridge.com/en/news/293825749.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293825749.md)
generator: "portal-rs"
---

# Gilead Sciences (GILD) Gets a Hold from RBC Capital

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences on July 23 and set a price target of $120.00. The company’s shares closed yesterday at $130.86.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Abrahams is a 5-star analyst with an average return of 14.5% and a 54.40% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Biogen, and Neurocrine.

In addition to RBC Capital, Gilead Sciences also received a Hold from Goldman Sachs’s Salveen Richter in a report issued on July 20. However, on July 23, BMO Capital assigned a Buy rating to Gilead Sciences (NASDAQ: GILD).

### Related Stocks

- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [GIS.DE](https://longbridge.com/en/quote/GIS.DE.md)
- [RY.US](https://longbridge.com/en/quote/RY.US.md)
- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [NBIX.US](https://longbridge.com/en/quote/NBIX.US.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [BMO.US](https://longbridge.com/en/quote/BMO.US.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)

## Related News & Research

- [Gilead Sciences (NASDAQ:GILD) CEO Sells 15,000 Shares of Stock](https://longbridge.com/en/news/297831169.md)
- [Gilead (GILD) Stock Stays Cheap After A 143% Five Year Run](https://longbridge.com/en/news/297410206.md)
- [New HIV and Breast Cancer Wins Might Change The Case For Investing In Gilead Sciences (GILD)](https://longbridge.com/en/news/297483843.md)
- [Is Gilead Sciences (GILD) Fully Valued On Its New HIV And Cancer Drug Approvals?](https://longbridge.com/en/news/297787019.md)
- [NEOS Investment Management LLC Has $120.08 Million Position in Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/298019220.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**